Abstract
Background: Stroke remains the second commonest cause of death and leading cause of adult disability worldwide. Ischemic events account for nearly 85% of all strokes, and hemorrhages account for nearly 15%. Stroke intervention and recovery have been identified as the important factors in the functional outcome of patients with completed stroke. However, the only FDA approved treatment for ischemic strokes is tissue plasminogen activator, and no effective targeted therapy for hemorrhagic stroke exists yet.
Methods: The goal of this work is to review the brain drug delivery systems (BDDS) used for stroke intervention and recovery. Results: Many novel BDDS have been developed for the use of stroke intervention and recovery, including nanoparticles, hydrogels, fibers, liposomes, and so on, which could improve the permeability of blood-brainbarrier (BBB), short half-life, stability in vivo, and reduce adverse effects of drugs. Conclusion: Combined with new drug targets in the treatment of stroke, BDDS will provide more effective therapeutics for stroke intervention and recovery.Keywords: Brain drug delivery, ischemic stroke, intracerebral hemorrhage, stroke intervention, stroke recovery.
Current Pharmaceutical Design
Title:Brain Drug Delivery Systems for the Stroke Intervention and Recovery
Volume: 23 Issue: 15
Author(s): Tiantian Luo, Ju Wang, Shilei Hao*, Tingwang Guo, Peng Ren, Zhongjun Cheng, Feiyan Gao, Yuhua Gong and Bochu Wang*
Affiliation:
- Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, Chongqing 400030,China
- Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, Chongqing 400030,China
Keywords: Brain drug delivery, ischemic stroke, intracerebral hemorrhage, stroke intervention, stroke recovery.
Abstract: Background: Stroke remains the second commonest cause of death and leading cause of adult disability worldwide. Ischemic events account for nearly 85% of all strokes, and hemorrhages account for nearly 15%. Stroke intervention and recovery have been identified as the important factors in the functional outcome of patients with completed stroke. However, the only FDA approved treatment for ischemic strokes is tissue plasminogen activator, and no effective targeted therapy for hemorrhagic stroke exists yet.
Methods: The goal of this work is to review the brain drug delivery systems (BDDS) used for stroke intervention and recovery. Results: Many novel BDDS have been developed for the use of stroke intervention and recovery, including nanoparticles, hydrogels, fibers, liposomes, and so on, which could improve the permeability of blood-brainbarrier (BBB), short half-life, stability in vivo, and reduce adverse effects of drugs. Conclusion: Combined with new drug targets in the treatment of stroke, BDDS will provide more effective therapeutics for stroke intervention and recovery.Export Options
About this article
Cite this article as:
Luo Tiantian, Wang Ju, Hao Shilei*, Guo Tingwang, Ren Peng, Cheng Zhongjun, Gao Feiyan, Gong Yuhua and Wang Bochu*, Brain Drug Delivery Systems for the Stroke Intervention and Recovery, Current Pharmaceutical Design 2017; 23 (15) . https://dx.doi.org/10.2174/1381612822666161025155058
DOI https://dx.doi.org/10.2174/1381612822666161025155058 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Rationale for Comparative Studies of Accelerated Atherosclerosis in Rheumatic Diseases
Current Vascular Pharmacology Prospective for Diagnosis and Treatment of Diabetic Retinopathy
Current Pharmaceutical Design Effects of Acute and Chronic Biomechanical Strain on Human Cerebral Endothelial Cells in Altering their Proteome Profile
Current Proteomics Health Benefits of Honey: Implications for Treating Cardiovascular Diseases
Current Nutrition & Food Science Atherogenesis in Renal Patients: A Model of Vascular Disease?
Current Vascular Pharmacology The Fabry Cardiomyopathy - Diagnostic Approach and Current Treatment
Current Pharmaceutical Design Secondary Prevention of Ischemic Stroke
Current Drug Targets Use of Telemetry Blood Pressure Transmitters to Measure Intracranial Pressure (ICP) in Freely Moving Rats
Current Neurovascular Research ESVS Guidelines: Section A - Prevention in Patients with Carotid Stenosis
Current Vascular Pharmacology Current Management and Treatment of Cerebral Vasospasm Complicating SAH
CNS & Neurological Disorders - Drug Targets Eye Disorders in Diabetes: Potential Drug Targets
Infectious Disorders - Drug Targets Anesthetic Cardioprotection: The Role of Adenosine
Current Pharmaceutical Design Scaling Down SAGE: from miniSAGE to microSAGE
Current Pharmaceutical Biotechnology The Appearance of Middle Meningeal Artery Fistulae After Willis Covered Stent for Traumatic Carotid-cavernous Fistulae: Two Case Reports
Current Medical Imaging Aortic Dissection: A Review of the Pathophysiology, Management and Prospective Advances
Current Cardiology Reviews The Rise and Fall of NMDA Antagonists for Ischemic Stroke
Current Molecular Medicine Fluoroquinolones and the Risk of Aortic Aneurysm or Aortic Dissection: A Systematic Review and Meta-Analysis
Cardiovascular & Hematological Agents in Medicinal Chemistry Imaging of Abdominal Aortic Aneurysm: The Present and the Future
Current Vascular Pharmacology Implications of microRNAs in the Pathogenesis of Atherosclerosis and Prospects for Therapy
Current Drug Targets Electroconvulsive Therapy in Child and Adolescent Psychiatry
Current Psychiatry Reviews